Gilead's (GILD +1.9%) once-daily Sofosbuvir hepatitis C drug met the goals of a fourth Phase III...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead's (GILD +1.9%) once-daily Sofosbuvir hepatitis C drug met the goals of a fourth Phase III study, this time in patients who had failed prior treatments. With all four trials providing positive results, Gilead is on track to file regulatory applications in the EU and U.S. in Q2. (PR)